Member Info for Hurst10

With upcoming news flow from AVA6000 and indeed AVA3996/ AVA2727D a complete re-rating of the therapeutic business is very likely and hence the current share price is a gift and the company come Q2 will be a very exciting therapeutic company with an incredible news flow ahead.

Worth reminding us that GenScript ProBio Signed CDMO Supply Agreement And Formed Strategic Partnership with AffyXell Therapeutics – A Joint Daewong-Avacta venture .GenScript also acquired more equity as well.At what valuation ? Ref Avacta's nil cost 20% holding.

Would be interesting to know at what valuation was their recent stake acquired at?

Read across to Avacta's nil cost holding in Affyxell !

Precision medicine was the talk of the town, especially on day three of the 2024 JPM conference.

It was very clear that precision medicine was one of the buzzwords at the 2024 JPM convention, along with artificial intelligence (AI).

AI in drug discovery is set to reach $5 billion in the next four years, as the technology aims to develop drugs quicker and cheaper.

There was also an heightened interest in AI and precision medicine directly, with a lot of interest AI-based soluble TCR therapeutics platform, which is generating precision medicines for oncology and auto-immune diseases,”.

AI in drug discovery is set to reach $5 billion in the next four years, as the technology aims to develop drugs quicker and cheaper.

Well why do you think they need their own tweets

Because it’s going through launch and Coris.

Relevant for Launch Diagnostics and Acacta

From Vox Markets

https://www.voxmarkets.co.uk/articles/vox-markets-fund-manager-series-gervais-williams-of-premier-miton-d6fb11c

The timing of this appointment is the clearest sign that the Therapeutic business carries top priority for Avacta and that AVA6000 will soon make more headlines and valuation of global Precision is going north pre ACCR.

Also worth reminding ourselves head therapeutics lives in the States!

175/ being crossed at the moment.

More to follow.

Meanwhile size buyers back in town!

Even more interesting is that the company is making very bullish noises about the potential of AVA3996 !

Since 06.00 AM NY 37buys vs 1 sale.

NY will get up earlier now and days and continue to pick up stock at this level, before any news.

Watch who will be on the bid.

Two new initial public offerings (IPO) are set to go ahead in the USA, raising hopes of a thaw in what has been a long winter for biotech companies going public.

Kyverna Therapeutics has filed paperwork with the US financial regulator for its IPO, which is targeting a fundraise of around $100 million.

Another Californian firm, Alto Neuroscience, has filed for an IPO of an undisclosed size.

One should remind yourself of what happened back in September:

"Avacta shares surged on Tuesday after CEO Dr Alastair Smith said he believed Avacta are ‘on the verge of a paradigm shift in how chemotherapy is delivered to cancer patients.”

UK biotech company Avacta Group has announced positive results from the latest cohort in its clinical trial of AVA6000, the company’s targeted chemotherapy drug".

Then remind yourself that in Avacta's case, "silence is golden", as the company has not published any negative test results.

Highly ranked directors have joined the company, the Therapeutic division will attract a tremendous amount of attention before and at the upcoming ACCR conference.

Investors taking advantage of current share price, will look very clever very soon!

-200,000

-200,000

-200,000

Post closure ticks.

Who is the buyer?

10-12 coming up and NY will step in and up the price further. (JBER)

Since 07.00AM NY 42 buys and 9 sells

SING and MREX on the bid

Worth remembering :

Most notably the Orphan Drug Designation will give Avacta, if AVA6000 is approved for treatment of soft tissue sarcoma, seven years of market exclusivity in the US, which is a significant commercial advantage.”

+

There is also a potential tax credit of 25%

Would the above also apply to AVA3996 I wonder.

Amgen may be evaluating

Cytokinetics bid;

CYTK wants $130-$145 a share - report

Meanwhile we have Lilly presenting at the conference later on today. One of the key topics is Radiopharma and the reason why they will avoid mega pharma deals( multi billion), but focus on specialist medicine.

Ideal license deal and partner, + ( they just acquired Point Biopharma).

So watch out for the company talking about their latest acquisition.